|
시장보고서
상품코드
2077845
간흡충증 시장 : 약물별, 유통 채널별, 지역별Fascioliasis Market, By Drug, By Distribution Channel, And by Region |
||||||
간흡충증 시장은 2026년에 4억 1,300만 달러 규모에 달할 것으로 추정되며, 2033년까지 5억 7,040만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.7%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 4억 1,300만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 4.70% | 2033년 시장 규모 예측: | 5억 7,040만 달러 |
간흡충증은 일반적으로 ‘일반 간흡충’ 또는 ‘양 간흡충’이라고도 불리는 Fasciola hepatica에 의해 발생하는 감염병입니다. 파시오라증은 주요 종인 Fasciola hepatica와 또 다른 관련 종인 Fasciola gigantica, 이 두 종의 파시오라에 의해 유발됩니다. Fasciola gigantica 역시 사람에게 감염될 가능성이 있습니다. Fasciola gigantica는 호주와 중국 등 일부 열대 지역에서 확인되고 있습니다. 간흡충증은 양이나 소가 사육되는 지역에서 발생합니다. 사람은 생 물냉이 또는 기타 오염된 담수 식물을 통해, 혹은 오염된 물을 마심으로써 실수로 간흡충을 섭취(삼키게)하여 감염됩니다. 그 밖의 감염 경로로는 오염된 물로 씻거나 관개한 채소를 섭취하는 경우가 있습니다. 특히 유행 지역의 방목지에서 채취한 생 물냉이 및 기타 수생 식물을 섭취하지 않음으로써 간흡충증 감염을 예방할 수 있습니다. 감염 초기에는 미성숙한 흡충이 장에서 복강이나 간으로 이동하는 과정에서 몸이 불편함을 느끼는 사람도 있습니다. 파시오라증은 치료도 가능하며, 예방도 가능합니다.
시장 역학
미국 식품의약국(FDA)의 제품 승인 등 제도적 전략의 채택 확대가 예측 기간 동안 전 세계 파시오라증 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2019년 2월, 제약회사 노바티스 AG는 6세 이상 환자의 간흡충증 치료제로 트리클라벤다졸(Egaten)이 미국 식품의약국(FDA)으로부터 승인을 받았다고 발표했습니다. 미국에서 트리클라벤다졸이 승인됨에 따라, 유행 국가에 대한 의약품 라이선스 부여 및 수입이 촉진되어, 필요할 때 충분한 양의 의약품을 확보할 수 있게 될 것으로 기대됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 간흡충증 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 간흡충증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 간흡충증 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 간흡충증 시장 : 약물별, 2021-2033년
제5장 세계의 간흡충증 시장 : 유통 채널별, 2021-2033년
제6장 세계의 간흡충증 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.07.08Fascioliasis Market is estimated to be valued at USD 413.0 Mn in 2026 and is expected to reach USD 570.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 413.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.70% | 2033 Value Projection: | USD 570.4 Mn |
Fascioliasis is an infectious disease usually caused by Fasciola hepatica, also called as the common liver fluke or the sheep liver fluke. Fascioliasis is caused by two fasciola species, the main species Fasciola hepatica, and another related species Fasciola gigantica, which also can infect people. Fasciola gigantica has been found in some tropical areas such as Australia, China. Fascioliasis is found where sheep or cattle are reared. People are infected with Fasciola when the parasite is accidentally ingested (swallowed) through raw watercress or other contaminated freshwater plants, and also by drinking contaminated water. Other ways include by eating vegetables that were washed or irrigated with contaminated water. Fasciola infection can be prevented by not eating raw watercress and other water plants, especially from endemic grazing areas. Some people feel sick during the early stage of infection, while immature flukes migrate from the intestine through the abdominal cavity and liver. Fasciola infection is both treatable and preventable.
Market Dynamics
Increasing adoption of inorganic strategies such as product approvals by the U.S. Food and Drug Administration is expected to drive the global fascioliasis market growth over the forecast period. For instance, in February 2019, Novartis AG, a pharmaceutical company, announced that they had received an approval from the U.S.Food and Drug Administration for triclabendazole (Egaten) for the treatment of fascioliasis in patients aged 6 years and older. The approval of triclabendazole in the U.S. is expected to facilitate drug licensing and import to endemic countries, to provide a help for the sufficient availability of the drug when needed.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global fascioliasis market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, AMGIS Lifescience Ltd., Romark, AbbVie Inc., Merck KGaA, AdvaCare Pharma, Intas Pharmaceuticals Ltd., Procyon Life Sciences, Adroit Pharmachem Pvt Ltd., Sun Pharmaceutical Industries Ltd., RV Lifesciences Limited, Grampus Laboratories, and Janssen Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global fascioliasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fascioliasis market
Detailed Segmentation:
- Global Fascioliasis Market, By Drug (Revenue, USD Mn, 2021 - 2033)
- Triclabendazole
- Albendazole
- Nitazoxanide
- Global Fascioliasis Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Fascioliasis Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- Company Profiles
- Novartis AG*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AMGIS Lifescience Ltd.
- Romark
- AbbVie Inc.
- Merck KGaA
- AdvaCare Pharma
- Intas Pharmaceuticals Ltd.
- Procyon Life Sciences
- Adroit Pharmachem Pvt Ltd.
- Sun Pharmaceutical Industries Ltd.
- RV Lifesciences Limited
- Grampus Laboratories
- Janssen Pharmaceuticals, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Guidelines
- Product launches
- Key Development
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
4. Global Fascioliasis Market, By Drug, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Triclabendazole
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Albendazole
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Nitazoxanide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Fascioliasis Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Fascioliasis Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AMGIS Lifescience Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Romark
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AdvaCare Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Procyon Life Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Adroit Pharmachem Pvt Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- RV Lifesciences Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Grampus Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Janssen Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
8. Section
- Research Methodology
- About Us
